Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron

5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists are used in the prevention of chemotherapy- induced, radiation-induced and postoperative nausea and vomiting. CYP2D6 polymorphisms can influence the metabolism of some of these drugs (i.e. ondansetron and tropisetron) thereby affecting drug e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Pharmacol Ther
Main Authors: Bell, Gillian C., Caudle, Kelly E., Whirl-Carrillo, Michelle, Gordon, Ronald J., Hikino, Keiko, Prows, Cynthia A., Gaedigk, Andrea, Agundez, Jose A.G., Sadhasivam, Senthilkumar, Klein, Teri E., Schwab, Matthias
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5479760/
https://ncbi.nlm.nih.gov/pubmed/28002639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.598
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados